

2024 BCBSNM ASO Specialty Pharmacy Prior Authorization Code List Effective 1/1/2024 (Updated October 2024)

This list includes procedure code changes for Medical Benefit Specialty Pharmacy that may require benefit prior authorization through Blue Cross Blue Shield of New Mexico effective Jan. 1, 2024 for BCBSNM Administrative Service Organization (ASO) members.

Use this document to view details for a procedure code, including:

- 1) Drug Product Name Brand (generic)
- 2) Reason for prior authorization where medical necessity review is required for both therapy and place of infusion (Infusion Site of Care) or for therapy only (Provider Administered Drug Therapy) and/or for Medical Oncology & Supportive Care 3) Effective date for when prior authorization was implemented at BCBSNM (provider administered drug therapy or infusion site of care) or Carelon Medical Benefits Management (requests for oncology drugs that are supported by an oncology diagnosis).

Utilization Management Process

This file is a searchable PDF.

Press "CTRL" and "F" keys at the same time to bring up the search box. Enter a procedure code or description of the service.

For Medical Policy information, please access the BCBSNM Medical Policy Website

For services that are handled by Carelon Medical Benefits Management, Call 1-866-455-8415 or Access Website https://www.careloninsights.com/medical-benefits-management/specialty-care

Code Description Managed By

| Procedure Code | Service Galegory | Code Description | Manageu by | Opuales |
|----------------|---|--|----------------------|--|
| J1551 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Cutaquig) 100 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25. |
| J1554 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Asceniv) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25. |
| Q5106 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Epoetin Alfa-Epbx Biosimilar (Retacrit) (For Non- Esrd Use) 1000 Units | Carelon or BCBSNM | Added to Infusion Site of Care 04/01/24. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25. |

| Q5115 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Rituximab-Abbs Biosimilar (Truxima) 10 Mg | Carelon or BCBSNM | Added to Infusion Site of Care 04/01/24. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25. |
|-------|---|---|----------------------|--|
| Q5119 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Rituximab-Pvvr Biosimilar (Ruxience) 10 Mg | Carelon or BCBSNM | Added to Infusion Site of Care 04/01/24. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25. |
| Q5123 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Rituximab-Arrx Biosimilar (Riabni) 10 Mg | Carelon or BCBSNM | Added to Infusion Site of Care 04/01/24. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25. |
| J0219 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Avalglucosidase Alfa- Ngpt 4 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J0485 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Belatacept 1 Mg | BCBSNM | Add to Infusion Site of Care effective 04/01/2024. Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS. |
| J0491 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Anifrolumab-Fnia 1 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J0517 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Benralizumab 1 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J0791 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Crizanlizumab-Tmca 5 Mg | | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J1301 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Edaravone 1 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J1302 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Sutimlimab-Jome 10 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J1303 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Ravulizumab-Cwvz 10 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J1305 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Evinacumab-Dgnb 5Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J1306 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Inclisiran 1 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J1823 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Inebilizumab-Cdon 1 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |

| J1930 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Lanreotide 1 Mg | BCBSNM | Add to Infusion Site of Care effective 04/01/2024. Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS. |
|-------|---|--|---------|---|
| J2353 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Octreotide Depot Form For Intramuscular Injection 1 Mg | BCBSNM | Add to Infusion Site of Care effective 04/01/2024. Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS. |
| J2354 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Octreotide Non-Depot Form For Subcutaneous Or Intravenous Injection 25 Mcg | BCBSNM | Add to Infusion Site of Care effective 04/01/2024. Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS. |
| J2356 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Tezepelumab-Ekko 1 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J2796 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Romiplostim 10 Micrograms | BCBSNM | Add to Infusion Site of Care effective 04/01/2024. Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS. |
| J3032 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Eptinezumab-Jjmr 1 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J3111 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Romosozumab-Aqqg 1 Mg | BCBSNM | Add to Infusion Site of Care effective 04/01/2024. Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS. |
| J3241 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Teprotumumab-Trbw 10 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| J7183 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Von Willebrand Factor Complex (Human) Wilate 1 I.U. Vwf:Rco | BCBSNM | Add to Infusion Site of Care effective 04/01/2024. Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS. |
| J9332 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Efgartigimod Alfa-Fcab 2Mg | | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| Q5109 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Infliximab-Qbtx Biosimilar (Ixifi) 10 Mg | BCBSNM | Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS. |
| C9169 | Medical Oncology & Supportive Care | Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti,Tevimbra,Anktiva,Hercessi,Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |
| C9170 | Medical Oncology & Supportive Care | Injection, tarlatamab-dlle, 1 mg | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti,Tevimbra,Anktiva,Hercessi,Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |

| C9399 | Medical Oncology & Supportive Care | Unclassified Drugs Or Biologicals | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti,Tevimbra,Anktiva,Hercessi,Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |
|-------|------------------------------------|--|---------|---|
| J0641 | Medical Oncology & Supportive Care | Injection Levoleucovorin Not Otherwise Specified 0.5 Mg | Carelon | Retire Effective 01/01/2025 |
| J3490 | Medical Oncology & Supportive Care | Unclassified Drugs | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti, Tevimbra, Anktiva, Hercessi, Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |
| J3590 | Medical Oncology & Supportive Care | Unclassified Biologics | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti,Tevimbra,Anktiva,Hercessi,Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |
| J9329 | Medical Oncology & Supportive Care | Injection, tislelizumab-jsgr, 1mg | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti,Tevimbra,Anktiva,Hercessi,Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |
| J9999 | Medical Oncology & Supportive Care | Not Otherwise Classified Antineoplastic Drugs | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti,Tevimbra,Anktiva,Hercessi,Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |

| Q5136 | Medical Oncology & Supportive Care | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg | Carelon | Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Add new drugs effective 10/01/24: Wyost/Jubbonti,Tevimbra,Anktiva,Hercessi,Imdeltra (all but Hercessi have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir, Nypozi, Rytelo |
|-------|--|--|---------|---|
| J1576 | Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Panzyga) Intravenous Non- Lyophilized (E.G. Liquid) 500 Mg | Carelon | Added to Medical Oncology & Supportive Care 04/01/24. Add to Provider Administered Drug Therapy 01/01/25. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J0172 | Provider Administered Drug Therapy | Injection, Aducanumab-Avwa, 2 Mg | BCBSNM | Add Effective 01/01/2025 |
| J0174 | Provider Administered Drug Therapy | Injection, Lecanemab-Irmb, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| J0175 | Provider Administered Drug Therapy | donanemab-azbt | BCBSNM | Add Effective 01/01/2025 |
| J0218 | Provider Administered Drug Therapy | Injection, Olipudase Alfa-Rpcp, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| J0223 | Provider Administered Drug Therapy | Injection, givosiran, 0.5 mg | BCBSNM | Add Effective 01/01/2025 |
| J0224 | Provider Administered Drug Therapy | Injection, lumasiran, 0.5 mg | BCBSNM | Add Effective 01/01/2025 |
| J0225 | Provider Administered Drug Therapy | Injection, vutrisiran, 1 mg | BCBSNM | Add Effective 01/01/2025 |
| J0589 | Provider Administered Drug Therapy | Injection, Daxibotulinumtoxina- Lanm, 1 Unit | BCBSNM | Add Effective 01/01/2025 |
| J1203 | Provider Administered Drug Therapy | Injection, Cipaglucosidase Alfa- Atga, 5 Mg | BCBSNM | Add Effective 01/01/2025 |
| J1304 | Provider Administered Drug Therapy | Injection, Tofersen, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| J1426 | Provider Administered Drug Therapy | Injection, Casimersen, 10 Mg | BCBSNM | Add Effective 01/01/2025 |
| J1427 | Provider Administered Drug Therapy | Injection, Viltolarsen, 10 Mg | BCBSNM | Add Effective 01/01/2025 |
| J1429 | Provider Administered Drug Therapy | Injection, Golodirsen, 10 Mg | BCBSNM | Add Effective 01/01/2025 |
| J1747 | Provider Administered Drug Therapy | Injection, Spesolimab-Sbzo, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| J2267 | Provider Administered Drug Therapy | mirikizumab-mrkz | BCBSNM | Add Effective 01/01/2025 |
| J2327 | Provider Administered Drug Therapy | Injection, Risankizumab-Rzaa, Intravenous, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| J2329 | Provider Administered Drug Therapy | Injection, Ublituximab-Xiiy, 1Mg | BCBSNM | Add Effective 01/01/2025 |
| J2508 | Provider Administered Drug Therapy | Injection, Pegunigalsidase Alfa- lwxj, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| J3247 | Provider Administered Drug Therapy | secukinumab (intravenous) | BCBSNM | Add Effective 01/01/2025 |

| J3393 | Provider Administered Drug Therapy | Injection, betibeglogene autotemcel, per treatment | BCBSNM | Add Effective 01/01/2025 |
|-------|---|--|----------------------|--|
| J3394 | Provider Administered Drug Therapy | Injection, lovotibeglogene autotemcel, per treatment | BCBSNM | Add Effective 01/01/2025 |
| J9333 | Provider Administered Drug Therapy | Injection, Rozanolixizumab-Noli, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| J9334 | Provider Administered Drug Therapy | Injection, Efgartigimod Alfa, 2 Mg And Hyaluronidase-Qvfc | BCBSNM | Add Effective 01/01/2025 |
| J9376 | Provider Administered Drug Therapy | Injection, Pozelimab-Bbfg, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| Q5133 | Provider Administered Drug Therapy | Injection, Tocilizumab-Bavi (Tofidence), Biosimilar, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| Q5134 | Provider Administered Drug Therapy | Injection, Natalizumab-Sztn (Tyruko), Biosimilar, 1 Mg | BCBSNM | Add Effective 01/01/2025 |
| Q5138 | Provider Administered Drug Therapy | ustekinumab-auub | BCBSNM | Add Effective 01/01/2025 |
| J0223 | Infusion Site of Care | Injection Givosiran 0.5 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0224 | Infusion Site of Care | Injection Lumasiran 0.5 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0881 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Darbepoetin Alfa 1 Microgram (Non-Esrd Use) | Carelon or BCBSNM | Added to Infusion Site of Care 04/01/24. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J0885 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Epoetin Alfa (For Non- Esrd Use) 1000 Units | Carelon or BCBSNM | Added to Infusion Site of Care 04/01/24. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1459 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Privigen) Intravenous Non- Lyophilized (E.G. Liquid) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1555 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Cuvitru) 100 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1556 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Bivigam) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1557 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Gammaplex) Intravenous Non- Lyophilized (E.G. Liquid) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |

| J1558 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Xembify) 100 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
|-------|---|---|----------------------|--|
| J1559 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Hizentra) 100 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1561 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Gamunex-C/Gammaked) Non- Lyophilized (E. G. Liquid) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1566 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin Intravenous Lyophilized (E. G. Powder) Not Otherwise Specified 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1568 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Octagam) Intravenous Nonlyophilized (E.G. Liquid) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1569 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Gammagard Liquid) Non- Lyophilized (E. G. Liquid) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1572 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin (Flebogamma/Flebogamma Dif) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J1575 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin/Hyaluronidase (Hyqvia) 100 Mg Immuneglobulin | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
| J9312 | Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Rituximab 10 Mg | Carelon or BCBSNM | Added to Infusion Site of Care 04/01/24. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |

| J0129 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Abatacept 10 Mg (Code May Be Used For Medicare When Drug Administered Under The Direct Supervision Of A Physician Not For Use When Drug Is Self Administered) | BCBSNM | Prior Authorization required through BCBS. |
|-------|--|---|--------|--|
| J0180 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Agalsidase Beta 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0221 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Alglucosidase Alfa (Lumizyme) 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0222 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Patisiran 0.1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0490 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Belimumab 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0584 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Burosumab-Twza 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0598 | Infusion Site of Care, Provider Administered Drug Therapy | Injection C-1 Esterase Inhibitor (Human) Cinryze 10 Units | BCBSNM | Prior Authorization required through BCBS. |
| J0638 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Canakinumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0717 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Certolizumab Pegol 1 Mg (Code May Be Used For Medicare When Drug Administered Under The Direct Supervision Of A Physician Not For Use When Drug Is Self Administered) | BCBSNM | Prior Authorization required through BCBS. |
| J1290 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Ecallantide 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1300 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Eculizumab 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1322 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Elosulfase Alfa 1Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1458 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Galsulfase 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1602 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Golimumab 1 Mg For Intravenous Use | BCBSNM | Prior Authorization required through BCBS. |
| J1743 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Idursulfase 1 Mg | BCBSNM | Prior Authorization required through BCBS. |

| J1745 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Infliximab Excludes Biosimilar 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
|-------|---|---|--------|--|
| J1746 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Ibalizumab-Uiyk 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1786 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Imiglucerase 10 Units | BCBSNM | Prior Authorization required through BCBS. |
| J1931 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Laronidase 0.1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2182 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Mepolizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2323 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Natalizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2350 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Ocrelizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2357 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Omalizumab 5 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2507 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Pegloticase 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2786 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Reslizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2840 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Sebelipase Alfa 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3060 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Taliglucerace Alfa 10 Units | BCBSNM | Prior Authorization required through BCBS. |
| J3245 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Tildrakizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3262 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Tocilizumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3358 | Infusion Site of Care, Provider Administered Drug Therapy | Ustekinumab For Intravenous Injection 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3380 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Vedolizumab Intravenous 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3385 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Velaglucerase Alfa 100 Units | BCBSNM | Prior Authorization required through BCBS. |
| J3397 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Vestronidase Alfa-Vjbk 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| Q5103 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Infliximab-Dyyb Biosimilar (Inflectra) 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| Q5104 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Infliximab-Abda Biosimilar (Renflexis) 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| Q5121 | Infusion Site of Care, Provider Administered Drug Therapy | Injection Infliximab-Axxq Biosimilar (Avsola) 10 Mg | BCBSNM | Prior Authorization required through BCBS. |

| C9163 | Medical Oncology & Supportive Care | Talvey (Talquetamab-Tgvs) | Carelon | Add Effective 04/01/2024, to be replaced by code J3055 7/1/24. Prior Authorization required through Carelon. |
|-------|------------------------------------|---|---------|--|
| C9165 | Medical Oncology & Supportive Care | Elrexfio (Elranatamab-Bcmm) | Carelon | Add Effective 07/01/2024, replaced code C9165 7/1/24. Prior Authorization required through Carelon. |
| J0642 | Medical Oncology & Supportive Care | Injection Levoleucovorin (Khapzory) 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| J0882 | Medical Oncology & Supportive Care | Injection Darbepoetin Alfa 1 Microgram (For Esrd On Dialysis) | Carelon | Prior Authorization required through Carelon. |
| J0896 | Medical Oncology & Supportive Care | Injection Luspatercept-Aamt 0.25 Mg | Carelon | Prior Authorization required through Carelon. |
| J0897 | Medical Oncology & Supportive Care | Injection Denosumab 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J1323 | Medical Oncology & Supportive Care | Injection Elranatamab-Bcmm 1 Mg | Carelon | Add Effective 04/01/2024, to be replaced by code J1323 7/1/24. Prior Authorization required through Carelon. |
| J1442 | Medical Oncology & Supportive Care | Injection Filgrastim (G-Csf) Excludes Biosimilars 1 Microgram | Carelon | Prior Authorization required through Carelon. |
| J1447 | Medical Oncology & Supportive Care | Injection Tbo-Filgrastim 1 Microgram | Carelon | Prior Authorization required through Carelon. |
| J1448 | Medical Oncology & Supportive Care | Injection Trilaciclib 1Mg | Carelon | Prior Authorization required through Carelon. |
| J1449 | Medical Oncology & Supportive Care | Injection Eflapegrastim-Xnst 0.1 Mg | Carelon | Prior Authorization required through Carelon. |
| J2506 | Medical Oncology & Supportive Care | Injection Pegfilgrastim Excludes Biosimilar 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| J2820 | Medical Oncology & Supportive Care | Injection Sargramostim (Gm- Csf) 50 Mcg | Carelon | Prior Authorization required through Carelon. |
| J2860 | Medical Oncology & Supportive Care | Injection Siltuximab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J3055 | Medical Oncology & Supportive Care | Injection Talquetamab-Tgvs 0.25 Mg | Carelon | Add Effective 07/01/2024, replaced code C9163 7/1/24. Prior Authorization required through Carelon. |
| J3263 | Medical Oncology & Supportive Care | Loqtorzi (toripalimab-tpzi) | Carelon | Add Effective 10/01/2024 |
| J9019 | Medical Oncology & Supportive Care | Injection Asparaginase (Erwinaze) 1 000 lu | Carelon | Prior Authorization required through Carelon. |
| J9021 | Medical Oncology & Supportive Care | Injection Asparaginase Recombinant (Rylaze) 0.1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9022 | Medical Oncology & Supportive Care | Injection Atezolizumab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9023 | Medical Oncology & Supportive Care | Injection Avelumab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9032 | Medical Oncology & Supportive Care | Injection Belinostat 10 Mg | Carelon | Prior Authorization required through Carelon. |

| J9035 | Medical Oncology & Supportive Care | Injection Bevacizumab 10 Mg | Carelon | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. (This code is no longer reviewed by BCBS effective 10/01/2024) |
|-------|------------------------------------|---|---------|---|
| J9037 | Medical Oncology & Supportive Care | Injection Belantamab Mafodontin-Blmf 0.5 Mg | Carelon | Retire Effective 04/01/24 |
| J9039 | Medical Oncology & Supportive Care | Injection Blinatumomab 1 Microgram | Carelon | Prior Authorization required through Carelon. |
| J9042 | Medical Oncology & Supportive Care | Injection Brentuximab Vedotin 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9043 | Medical Oncology & Supportive Care | Injection Cabazitaxel 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9047 | Medical Oncology & Supportive Care | Injection Carfilzomib 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9055 | Medical Oncology & Supportive Care | Injection Cetuximab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9057 | Medical Oncology & Supportive Care | Injection Copanlisib 1 Mg | Carelon | Retire Effective 04/01/24 |
| J9061 | Medical Oncology & Supportive Care | Injection Amivantamab-Vmjw 2 Mg | Carelon | Prior Authorization required through Carelon. |
| J9063 | Medical Oncology & Supportive Care | Injection Mirvetuximab Soravtansine-Gynx 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9064 | Medical Oncology & Supportive Care | Injection Cabazitaxel (Sandoz) Not Therapeutically Equivalent To J9043 1 Mg | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J9118 | Medical Oncology & Supportive Care | Injection Calaspargase Pegol- Mknl 10 Units | Carelon | Prior Authorization required through Carelon. |
| J9119 | Medical Oncology & Supportive Care | Injection Cemiplimab-Rwlc 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9144 | Medical Oncology & Supportive Care | Injection Daratumumab 10 Mg And Hyaluronidase-Fihj | Carelon | Prior Authorization required through Carelon. |
| J9145 | Medical Oncology & Supportive Care | Injection Daratumumab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9153 | Medical Oncology & Supportive Care | Injection Liposomal 1 Mg Daunorubicin And 2.27 Mg Cytarabine | Carelon | Prior Authorization required through Carelon. |
| J9173 | Medical Oncology & Supportive Care | Injection Durvalumab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9176 | Medical Oncology & Supportive Care | Injection Elotuzumab 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9177 | Medical Oncology & Supportive Care | Injection Enfortumab Vedotin- Ejfv 0.25 Mg | Carelon | Prior Authorization required through Carelon. |
| J9179 | Medical Oncology & Supportive Care | Injection Eribulin Mesylate 0.1 | Carelon | Prior Authorization required through Carelon. |
| J9203 | Medical Oncology & Supportive Care | Injection Gemtuzumab Ozogamicin 0.1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9204 | Medical Oncology & Supportive Care | Injection Mogamulizumab-Kpkc 1 Mg | Carelon | Prior Authorization required through Carelon. |

| J9205 | Medical Oncology & Supportive Care | Injection Irinotecan Liposome 1 Mg | Carelon | Prior Authorization required through Carelon. |
|-------|------------------------------------|---|---------|---|
| J9207 | Medical Oncology & Supportive Care | Injection Ixabepilone 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9223 | Medical Oncology & Supportive Care | Injection Lurbinectedin 0.1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9227 | Medical Oncology & Supportive Care | Injection Isatuximab-Irfc 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9228 | Medical Oncology & Supportive Care | Injection Ipilimumab 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9229 | Medical Oncology & Supportive Care | Injection Inotuzumab Ozogamicin 0.1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9258 | Medical Oncology & Supportive Care | Injection Paclitaxel Protein- Bound Particles (Teva) Not Therapeutically Equivalent To J9264 1 Mg | Carelon | Add Effective 07/01/24 |
| J9259 | Medical Oncology & Supportive Care | Injection Paclitaxel Protein- Bound Particles (American Regent) Not Therapeutically Equivalent To J9264 1 Mg | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J9264 | Medical Oncology & Supportive Care | Injection Paclitaxel Protein- Bound Particles 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9266 | Medical Oncology & Supportive Care | Injection Pegaspargase Per Single Dose Vial | Carelon | Prior Authorization required through Carelon. |
| J9269 | Medical Oncology & Supportive Care | Injection Tagraxofusp-Erzs 10 Micrograms | Carelon | Prior Authorization required through Carelon. |
| J9271 | Medical Oncology & Supportive Care | Injection Pembrolizumab 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9272 | Medical Oncology & Supportive Care | Injection Dostarlimab-Gxly 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9273 | Medical Oncology & Supportive Care | Injection Tisotumab Vedotin- Tftv 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9274 | Medical Oncology & Supportive Care | Injection Tebentafusp-Tebn 1 Microgram | Carelon | Prior Authorization required through Carelon. |
| J9281 | Medical Oncology & Supportive Care | Mitomycin Pyelocalyceal Instillation 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9286 | Medical Oncology & Supportive Care | Injection Glofitamab-Gxbm 2.5 Mg | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J9295 | Medical Oncology & Supportive Care | Injection Necitumumab 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9298 | Medical Oncology & Supportive Care | Injection Nivolumab And Relatlimab-Rmbw 3 Mg/1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9299 | Medical Oncology & Supportive Care | Injection Nivolumab 1 Mg | Carelon | Prior Authorization required through Carelon. |

| J9301 | Medical Oncology & Supportive Care | Injection Obinutuzumab 10 Mg | Carelon | Prior Authorization required through Carelon. |
|-------|------------------------------------|---|---------|---|
| J9302 | Medical Oncology & Supportive Care | Injection Ofatumumab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9303 | Medical Oncology & Supportive Care | Injection Panitumumab 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9306 | Medical Oncology & Supportive Care | Injection Pertuzumab 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9308 | Medical Oncology & Supportive Care | Injection Ramucirumab 5 Mg | Carelon | Prior Authorization required through Carelon. |
| J9309 | Medical Oncology & Supportive Care | Injection Polatuzumab Vedotin- Piiq 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9311 | Medical Oncology & Supportive Care | Injection Rituximab 10 Mg And Hyaluronidase | Carelon | Prior Authorization required through Carelon. |
| J9313 | Medical Oncology & Supportive Care | Injection Moxetumomab Pasudotox-Tdfk 0.01 Mg | Carelon | Retire Effective 04/01/24 |
| J9316 | Medical Oncology & Supportive Care | Injection Pertuzumab Trastuzumab And Hyaluronidase-Zzxf Per 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9317 | Medical Oncology & Supportive Care | Injection Sacituzumab Govitecan-Hziy 2.5 Mg | Carelon | Prior Authorization required through Carelon. |
| J9321 | Medical Oncology & Supportive Care | Injection Epcoritamab-Bysp 0.16 Mg | Carelon | Add Effective 04/01/2024. Prior Authorization required through Carelon. |
| J9325 | Medical Oncology & Supportive Care | Injection Talimogene Laherparepvec Per 1 Million Plaque Forming Units | Carelon | Prior Authorization required through Carelon. |
| J9331 | Medical Oncology & Supportive Care | Injection Sirolimus Protein- Bound Particles 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9345 | Medical Oncology & Supportive Care | Injection Retifanlimab-Dlwr 1 Mg | Carelon | Add Effective 01/01/2024. Prior Authorization required through Carelon. |
| J9347 | Medical Oncology & Supportive Care | Injection Tremelimumab-Actl 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9348 | Medical Oncology & Supportive Care | Injection Naxitamab-Gqgk 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9349 | Medical Oncology & Supportive Care | Injection Tafasitamab-Cxix 2 Mg | Carelon | Prior Authorization required through Carelon. |
| J9350 | Medical Oncology & Supportive Care | Injection Mosunetuzumab-Axgb 1 Mg | Carelon | Add Effective 01/01/2024. Prior Authorization required through Carelon. |
| J9352 | Medical Oncology & Supportive Care | Injection Trabectedin 0.1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9353 | Medical Oncology & Supportive Care | Injection Margetuximab-Cmkb 5 Mg | Carelon | Prior Authorization required through Carelon. |

| J9354 | Medical Oncology & Supportive Care | Injection Ado-Trastuzumab Emtansine 1 Mg | Carelon | Prior Authorization required through Carelon. |
|-------|------------------------------------|---|---------|---|
| J9355 | Medical Oncology & Supportive Care | Injection Trastuzumab Excludes Biosimilar 10 Mg | Carelon | Prior Authorization required through Carelon. |
| J9356 | Medical Oncology & Supportive Care | Injection Trastuzumab 10 Mg And Hyaluronidase-Oysk | Carelon | Prior Authorization required through Carelon. |
| J9358 | Medical Oncology & Supportive Care | Injection Fam-Trastuzumab Deruxtecan-Nxki 1 Mg | Carelon | Prior Authorization required through Carelon. |
| J9359 | Medical Oncology & Supportive Care | Injection Loncastuximab Tesirine-Lpyl 0.075 Mg | Carelon | Prior Authorization required through Carelon. |
| J9361 | Medical Oncology & Supportive Care | Ryzneuta (efbemalenograstim alfa-vuxw) | Carelon | Add Effective 10/01/2024 |
| J9380 | Medical Oncology & Supportive Care | Injection Teclistamab-Cqyv 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| Q2043 | Medical Oncology & Supportive Care | Sipuleucel-T Minimum Of 50 Million Autologous Cd54+ Cells Activated With Pap-Gm-Csf Including Leukapheresis And All Other Preparatory Procedures Per Infusion | Carelon | Prior Authorization required through Carelon. |
| Q2049 | Medical Oncology & Supportive Care | Injection Doxorubicin Hydrochloride Liposomal Imported Lipodox 10 Mg | Carelon | Retire Effective 04/01/24 |
| Q2050 | Medical Oncology & Supportive Care | Injection Doxorubicin Hydrochloride Liposomal Not Otherwise Specified 10Mg | Carelon | Prior Authorization required through Carelon. |
| Q4081 | Medical Oncology & Supportive Care | Injection Epoetin Alfa 100 Units (For Esrd On Dialysis) | Carelon | Prior Authorization required through Carelon. |
| Q5101 | Medical Oncology & Supportive Care | Injection Filgrastim-Sndz Biosimilar (Zarxio) 1 Microgram | Carelon | Prior Authorization required through Carelon. |
| Q5105 | Medical Oncology & Supportive Care | Injection Epoetin Alfa-Epbx Biosimilar (Retacrit) (For Esrd On Dialysis) 100 Units | Carelon | Prior Authorization required through Carelon. |
| Q5107 | Medical Oncology & Supportive Care | Injection Bevacizumab-Awwb Biosimilar (Mvasi) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5108 | Medical Oncology & Supportive Care | Injection Pegfilgrastim-Jmdb (Fulphila) Biosimilar 0.5 Mg | Carelon | Prior Authorization required through Carelon. |

| Q5110 | Medical Oncology & Supportive Care | Injection Filgrastim-Aafi Biosimilar (Nivestym) 1 Microgram | Carelon | Prior Authorization required through Carelon. |
|-------|------------------------------------|---|---------|---|
| Q5111 | Medical Oncology & Supportive Care | Injection Pegfilgrastim-Cbqv (Udenyca) Biosimilar 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5112 | Medical Oncology & Supportive Care | Injection Trastuzumab-Dttb Biosimilar (Ontruzant) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5113 | Medical Oncology & Supportive Care | Injection Trastuzumab-Pkrb Biosimilar (Herzuma) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5114 | Medical Oncology & Supportive Care | Injection Trastuzumab-Dkst Biosimilar (Ogivri) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5116 | Medical Oncology & Supportive Care | Injection Trastuzumab-Qyyp Biosimilar (Trazimera) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5117 | Medical Oncology & Supportive Care | Injection Trastuzumab-Anns Biosimilar (Kanjinti) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5118 | Medical Oncology & Supportive Care | Injection Bevacizumab-Bvzr Biosimilar (Zirabev) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5120 | Medical Oncology & Supportive Care | Injection Pegfilgrastim-Bmez (Ziextenzo) Biosimilar 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5122 | Medical Oncology & Supportive Care | Injection Pegfilgrastim-Apgf (Nyvepria) Biosimilar 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5125 | Medical Oncology & Supportive Care | Injection Filgrastim-Ayow Biosimilar (Releuko) 1 Microgram | Carelon | Prior Authorization required through Carelon. |
| Q5126 | Medical Oncology & Supportive Care | Injection Bevacizumab-Maly Biosimilar (Alymsys) 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5127 | Medical Oncology & Supportive Care | Injection Pegfilgrastim-Fpgk (Stimufend) Biosimilar 0.5 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5129 | Medical Oncology & Supportive Care | Injection Bevacizumab-Adcd (Vegzelma) Biosimilar 10 Mg | Carelon | Prior Authorization required through Carelon. |
| Q5130 | Medical Oncology & Supportive Care | Injection Pegfilgrastim-Pbbk (Fylnetra) Biosimilar 0.5 Mg | Carelon | Prior Authorization required through Carelon. |

| J1599 | Medical Oncology & Supportive Care, Provider Administered Drug Therapy | Injection Immune Globulin Intravenous Non-Lyophilized (E.G. Liquid) Not Otherwise Specified 500 Mg | Carelon or BCBSNM | Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. |
|-------|--|---|----------------------|---|
| 90283 | Provider Administered Drug Therapy | Immune Globulin (Igiv) Human For Intravenous Use | BCBSNM | Prior Authorization required through BCBS. |
| 90284 | Provider Administered Drug Therapy | Immune Globulin (Scig) Human For Use In Subcutaneous Infusions 100 Mg Each | BCBSNM | Prior Authorization required through BCBS. |
| 90378 | Provider Administered Drug Therapy | Respiratory Syncytial Virus Monoclonal Antibody Recombinant For Intramuscular Use 50 Mg Each | BCBSNM | Prior Authorization required through BCBS. |
| C9257 | Provider Administered Drug Therapy | Injection Bevacizumab 0.25 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J0202 | Provider Administered Drug Therapy | Injection Alemtuzumab 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0565 | Provider Administered Drug Therapy | Injection Bezlotoxumab 10 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J0567 | Provider Administered Drug Therapy | Injection Cerliponase Alfa 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0585 | Provider Administered Drug Therapy | Injection Onabotulinumtoxina 1 Unit | BCBSNM | Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS. |
| J0586 | Provider Administered Drug Therapy | Injection Abobotulinumtoxina 5 Units | BCBSNM | Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS. |
| J0587 | Provider Administered Drug Therapy | Injection Rimabotulinumtoxinb 100 Units | BCBSNM | Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS. |
| J0588 | Provider Administered Drug Therapy | Injection Incobotulinumtoxin A 1 Unit | BCBSNM | Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS. |
| J0741 | Provider Administered Drug Therapy | Injection Cabotegravir And Rilpivirine 2Mg/3Mg | BCBSNM | Add Effective 07/01/2024. Prior Authorization required through BCBS. |
| J0775 | Provider Administered Drug Therapy | Injection Collagenase Clostridium Histolyticum 0.01 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J0888 | Provider Administered Drug Therapy | Injectin Epoetin Beta 1 Microgram (For Non Esrd Use) | BCBSNM | Prior Authorization required through BCBS. |

| J1325 | Provider Administered Drug Therapy | Injection Epoprostenol 0.5 Mg | BCBSNM | Retire Effective 10/01/2024 |
|-------|------------------------------------|--|--------|--|
| J1411 | Provider Administered Drug Therapy | Injection Etranacogene Dezaparvovec-Drlb Per Therapeutic Dose | BCBSNM | Add effective 01/01/2024. Prior Authorization required through BCBS. |
| J1412 | Provider Administered Drug Therapy | Injection Valoctocogene Roxaparvovec-Rvox Per MI Containing Nominal 2 X 10^13 Vector Genomes | BCBSNM | Add effective 04/01/2024. Prior Authorization required through BCBS. |
| J1413 | Provider Administered Drug Therapy | Injection Delandistrogene Moxeparvovec-Rokl Per Therapeutic Dose | BCBSNM | Add effective 04/01/2024. Prior Authorization required through BCBS. |
| J1428 | Provider Administered Drug Therapy | Injection Eteplirsen 10 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1562 | Provider Administered Drug Therapy | Injection Immune Globulin (Vivaglobin) 100 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J1675 | Provider Administered Drug Therapy | Injection Histrelin Acetate 10 Micrograms | BCBSNM | Retire Effective 10/01/2024 |
| J1726 | Provider Administered Drug Therapy | Injection Hydroxyprogesterone Caproate (Makena) 10 Mg | BCBSNM | Retire Effective 01/01/2024. |
| J1950 | Provider Administered Drug Therapy | Injection Leuprolide Acetate (For Depot Suspension) Per 3. 75 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J1961 | Provider Administered Drug Therapy | Injection Lenacapavir 1 Mg | BCBSNM | Add Effective 07/01/2024. Prior Authorization required through BCBS. |
| J2278 | Provider Administered Drug Therapy | Injection Ziconotide 1 Microgram | BCBSNM | Retire Effective 10/01/2024 |
| J2326 | Provider Administered Drug Therapy | Injection Nusinersen 0.1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2502 | Provider Administered Drug Therapy | Injection Pasireotide Long Acting 1 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J2562 | Provider Administered Drug Therapy | Injection Plerixafor 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J2941 | Provider Administered Drug Therapy | Injection Somatropin 1 Mg | BCBSNM | Prior Authorization required through BCBS. |
| J3121 | Provider Administered Drug Therapy | Injection Testosterone Enanthate 1Mg | BCBSNM | Retire Effective 10/01/2024 |
| J3145 | Provider Administered Drug Therapy | Injection Testosterone Undecanoate 1 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J3285 | Provider Administered Drug Therapy | Injection Treprostinil 1 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J3315 | Provider Administered Drug Therapy | Injection Triptorelin Pamoate 3. 75 Mg | | Retire Effective 10/01/2024 |
| J3398 | Provider Administered Drug Therapy | Injection Voretigene Neparvovec-Rzyl 1 Billion Vector Genomes | BCBSNM | Prior Authorization required through BCBS. |

| J3399 | Provider Administered Drug Therapy | Injection Onasemnogene Abeparvovec-Xioi Per Treatment Up To 5X10^15 Vector Genomes | BCBSNM | Prior Authorization required through BCBS. |
|-------|------------------------------------|---|--------|--|
| J3401 | Provider Administered Drug Therapy | Beremagene Geperpavec-Svdt For Topical Administration Containing Nominal 5 X 10^9 Pfu/MI Vector Genomes Per 0.1 MI | BCBSNM | Add effective 04/01/2024. Prior Authorization required through BCBS. |
| J7178 | Provider Administered Drug Therapy | Injection Human Fibrinogen Concentrate Not Otherwise Specified 1 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J7340 | Provider Administered Drug Therapy | Carbidopa 5 Mg/Levodopa 20 Mg Enteral Suspension 100 MI | BCBSNM | Retire Effective 10/01/2024 |
| J9029 | Provider Administered Drug Therapy | Intravesical Instillation Nadofaragene Firadenovec- Vncg Per Therapeutic Dose | BCBSNM | Add effective 01/01/2024. Prior Authorization required through BCBS. |
| J9155 | Provider Administered Drug Therapy | Injection Degarelix 1 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J9202 | Provider Administered Drug Therapy | Goserelin Acetate Implant Per 3. 6 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J9217 | Provider Administered Drug Therapy | Leuprolide Acetate (For Depot Suspension) 7.5 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J9218 | Provider Administered Drug Therapy | Leuprolide Acetate Per 1 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J9219 | Provider Administered Drug Therapy | Leuprolide Acetate Implant 65 Mg | BCBSNM | Retire Effective 10/01/2024 |
| J9225 | Provider Administered Drug Therapy | Histrelin Implant (Vantas) 50 Mg | | Retire Effective 10/01/2024 |
| J9226 | Provider Administered Drug Therapy | Histrelin Implant (Supprelin La) 50 Mg | BCBSNM | Retire Effective 10/01/2024 |
| Q2041 | Provider Administered Drug Therapy | Axicabtagene Ciloleucel Up To 200 Million Autologous Anti- Cd19 Car Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose | BCBSNM | Prior Authorization required through BCBS. |
| Q2042 | Provider Administered Drug Therapy | Tisagenlecleucel Up To 600 Million Car-Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose | BCBSNM | Prior Authorization required through BCBS. |

| Q2053 | Provider Administered Drug Therapy | Brexucabtagene Autoleucel Up To 200 Million Autologous Anti- Cd19 Car Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose | BCBSNM | Prior Authorization required through BCBS. |
|-------|------------------------------------|--|--------|--|
| Q2054 | Provider Administered Drug Therapy | Lisocabtagene Maraleucel Up To 110 Million Autologous Anti- Cd19 Car-Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose | BCBSNM | Prior Authorization required through BCBS. |
| Q2055 | Provider Administered Drug Therapy | Idecabtagene Vicleucel Up To 460 Million Autologous B-Cell Maturation Antigen (Bcma) Directed Car-Positive T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose | BCBSNM | Prior Authorization required through BCBS. |
| Q2056 | Provider Administered Drug Therapy | Ciltacabtagene Autoleucel Up To 100 Million Autologous B-Cell Maturation Antigen (Bcma) Directed Car-Positive T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose | BCBSNM | Prior Authorization required through BCBS. |
| S0157 | Provider Administered Drug Therapy | Becaplermin Gel 0. 01% 0. 5 Gm | BCBSNM | Retire Effective 10/01/2024 |
| S0189 | Provider Administered Drug Therapy | Testosterone Pellet 75Mg | BCBSNM | Retire Effective 10/01/2024 |

Important Notes:

Prior authorization is required for some members/services/drugs before services are rendered to confirm medical necessity as defined by the member's health benefit plan.

Usually, the provider is responsible for requesting prior authorization before performing a service if the member is seeing an in-network provider. Sometimes, a plan may require the member to request prior authorization for services.

Once a prior authorization request is received and processed, the decision is communicated to the provider.

If you have questions, call the prior authorization number on the member's ID card.

This is not an exhaustive list of all codes. Codes may change, and this list may be updated throughout the year. The presence of codes on this list does not necessarily indicate coverage under the member benefits contract. Member contracts differ in their benefits. Always check eligibility and benefits first through the Availity® Essentials (availity.com) or your preferred web vendor portal to confirm coverage and other important details, including prior authorization or pre-notification requirements and vendors, if applicable. For some services/members, prior authorization may be required through Blue Cross and Blue Shield of MT. For other services/members, BCBSNM has contracted with Carelon Medical Benefits Management for utilization management and related services.

CPT copyright 2023 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

Please note that checking eligibility and benefits and/or the fact that a service has received prior authorization is not a guarantee of payment. Benefits will be determined once a claim is received and will be based upon, among other things, the member's eligibility and the terms of the member's certificate of coverage applicable on the date services were rendered.

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSNM.

Carelon Medical Benefits Management is an independent company that has contracted with BCBSNM to provide utilization management services for members with coverage through BCBSNM.

BCBSNM makes no endorsement, representations or warranties regarding any products or services provided by third party vendors such as Availity or Carelon Medical Benefits Management.Please contact the vendor(s) directly for any questions regarding products or services offered.

Blue Cross and Blue Shield of New Mexico, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association.